Lenabasum 20 mg + Lenabasum 5 mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis
Conditions
Dermatomyositis
Trial Timeline
Dec 17, 2018 → Oct 5, 2021
NCT ID
NCT03813160About Lenabasum 20 mg + Lenabasum 5 mg + Placebo
Lenabasum 20 mg + Lenabasum 5 mg + Placebo is a phase 3 stage product being developed by Corbus Pharmaceuticals for Dermatomyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT03813160. Target conditions include Dermatomyositis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03813160 | Phase 3 | Completed |
Competing Products
14 competing products in Dermatomyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| M5049 high dose + Placebo | Merck | Phase 2 | 52 |
| BAF312 + Placebo | Novartis | Phase 2 | 52 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 32 |
| Etanercept + Placebo | Amgen | Phase 1 | 32 |
| Dazukibart | Pfizer | Phase 3 | 76 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 51 |
| PF-06823859 low + Placebo Arm + PF-06823859 high | Pfizer | Phase 2 | 51 |
| Tofacitinib | Pfizer | Phase 1 | 32 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 51 |
| human immunoglobulin G + Placebo | CSL | Phase 3 | 76 |
| Empasiprubart IV | Argenx | Phase 2 | 49 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 47 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 44 |